Get the Stockscreener App
5.85
2.01%
-0.12
Tenax Therapeutics Inc stock is traded at $5.85, with a volume of 8,091.
It is down -2.01% in the last 24 hours and down -3.31% over the past month.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
See More
Previous Close:
$5.97
Open:
$6.17
24h Volume:
8,091
Relative Volume:
0.51
Market Cap:
$23.83M
Revenue:
-
Net Income/Loss:
$-14.56M
P/E Ratio:
-0.3478
EPS:
-16.82
Net Cash Flow:
$-12.46M
1W Performance:
+1.04%
1M Performance:
-3.31%
6M Performance:
-7.14%
1Y Performance:
+96.31%
1-Day Range:
$5.80
$6.17
1-Week Range:
$5.616
$6.75
52-Week Range:
$2.80
$7.89
Tenax Therapeutics Inc Stock (TENX) Company Profile
Name
Tenax Therapeutics Inc
Sector
Industry
Phone
919-855-2100
Address
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
5.85 | 23.83M | 0 | -14.56M | -12.46M | -16.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | Leerink Partners | Outperform |
| Oct-14-24 | Initiated | Guggenheim | Buy |
| Sep-30-24 | Initiated | William Blair | Outperform |
| May-18-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-16-14 | Initiated | MLV & Co | Buy |
| Nov-18-14 | Initiated | WallachBeth | Buy |
View All
Tenax Therapeutics Inc Stock (TENX) Latest News
Tenax Therapeutics Approves Officer Exculpation Amendment - TipRanks
Two Sigma Investments LP Acquires Shares of 13,521 Tenax Therapeutics, Inc. (NASDAQ:TENX) - Defense World
Millennium Management LLC Acquires New Holdings in Tenax Therapeutics, Inc. (NASDAQ:TENX) - Defense World
When (TENX) Moves Investors should Listen - news.stocktradersdaily.com
Where are the Opportunities in (TENX) - news.stocktradersdaily.com
Tectonic, Tenax, others aim for shift in heart failure - BioWorld MedTech
Tenax Therapeutics Reports Increased Losses Amid Strategic Investments - TipRanks
Roth Capital Issues Negative Forecast for TENX Earnings - Defense World
William Blair Cuts Earnings Estimates for Tenax Therapeutics - Defense World
Leerink Partnrs Brokers Boost Earnings Estimates for TENX - Defense World
(TENX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
What is William Blair’s Estimate for TENX FY2028 Earnings? - Defense World
Roth Capital Has Bearish Forecast for TENX FY2028 Earnings - Defense World
Tenax Therapeutics (NASDAQ:TENX) Now Covered by StockNews.com - Defense World
Tenax Therapeutics: Q1 Earnings Snapshot - Bluefield Daily Telegraph
Tenax Therapeutics (TENX) Projects Funding Through 2027 | TENX S - GuruFocus
Analyst Adjusts Tenax Therapeutics (TENX) Price Target, Maintains Buy Rating | TENX Stock News - GuruFocus
Tenax Therapeutics (TENX) Advances Phase 3 Studies in 2025 | TEN - GuruFocus
Tenax Therapeutics Inc Reports Q1 2025 Net Loss of $10.4 Million Amid Rising R&D and Administrative Expenses - GuruFocus
Tenax Therapeutics (TENX) Projects Funding Through 2027 | TENX Stock News - GuruFocus
Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Tenax Advances Breakthrough PH-HFpEF Treatment: Phase 3 Trial Updates and $111M War Chest Revealed - Stock Titan
Tenax Therapeutics (TENX) Projected to Post Earnings on Tuesday - Defense World
(TENX) Technical Data - news.stocktradersdaily.com
Tenax Therapeutics (NASDAQ:TENX) Coverage Initiated by Analysts at StockNews.com - Defense World
Geode Capital Management LLC Boosts Stock Position in Tenax Therapeutics, Inc. (NASDAQ:TENX) - Defense World
Tenax Therapeutics (NASDAQ:TENX) Coverage Initiated at StockNews.com - Defense World
Form SC 13G/AStatement of Beneficial Ownership by Certain Investors: [Amend] - ADVFN
SEC Form DEF 14A filed by Tenax Therapeutics Inc. - Quantisnow
Form DEF 14A TENAX THERAPEUTICS, INC. For: Apr 24 - StreetInsider
Tenax Therapeutics Advances Cardiopulmonary Therapies - TipRanks
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - The Globe and Mail
Oxygen Biotherapeutics, Inc. : Oxygen Biotherapeutics Announces Third Quarter FY2013 Financial Results Conference Call and Webcast - marketscreener.com
Teanx Therapeutics plans secondary offering - MSN
Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts - Seeking Alpha
Tenax Therapeutics (TENX) Files Prospectus for Stock Resale - GuruFocus
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Exclusive: Tenax Leadership Team to Unveil Latest Phase 3 Progress at Major Healthcare Conference - Stock Titan
What is Leerink Partnrs’ Forecast for TENX Q1 Earnings? - Defense World
Equities Analysts Offer Predictions for TENX Q1 Earnings - Defense World
Q1 Earnings Estimate for TENX Issued By William Blair - Defense World
Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com - Defense World
Research Analysts Set Expectations for TENX Q1 Earnings - Defense World
Tenax Therapeutics Inc Stock (TENX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):